HOUSTON, TX, May 18, 2026 - HeartLung Corporation announced the publication of a new study in the American Journal of Preventive Cardiology titled “Comparing Incidence of Heart Failure in Individuals with Enlarged Cardiac Chambers versus Diabetes.” The study demonstrates that HeartLung’s AI-CVD AutoChamber module can opportunistically identify left atrial enlargement, left ventricular enlargement, and increased left ventricular mass from routine coronary artery calcium scans,

Accepted studies showcase HeartLung.AI’s leadership in AI-CVD, opportunistic CT screening, Agatston 2.0, chamber volumetry, and preventive cardiology. HOUSTON, Texas, 05/11/2026 – HeartLung.AI today announced that 10 scientific abstracts have been accepted for presentation at ESC Congress 2026, the annual meeting of the European Society of Cardiology. The accepted studies showcase HeartLung.AI’s growing leadership in AI–enabled cardiovascular imaging and preventive cardiology

New intellectual property milestones strengthen HeartLung’s leadership in AI–enabled preventive CT imaging and coronary inflammation assessment HOUSTON, TX, UNITED STATES, May 3, 2026 /EINPresswire.com/ -- HeartLung Corporation, a medical technology company advancing AI–enabled, CT–based opportunistic screening and early disease detection, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,620,494, titled “Predicting adverse healt

CMS Code G0680 opens doors to AI-enabled opportunistic detection of patients with silent coronary artery disease who are unaware of their risk of a future heart attack. HOUSTON, April 7, 2026 -- HeartLung AI today welcomed CMS’s establishment of HCPCS code G0680 in the April 2026 Hospital Outpatient Prospective Payment System update, effective April 1, 2026, for algorithmic analysis of coronary artery calcium (CAC) and/or aortic valve calcification from chest CT with report.

Houston, TX – [March 18, 2026] – HeartLung Technologies today announced strong support for the newly released 2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia, which introduces a major paradigm shift in cardiovascular prevention: the formal recognition of opportunistic detection of coronary artery calcium (CAC) on routine noncardiac CT scans, including the use of validated artificial intelligence algorithms. For the first time, leading cardiovascular soci

AutoChamber™ and AutoBMD™ AI solutions will soon be available on Precision Imaging Network, with AI-CVD® planned next. HOUSTON, TX, UNITED STATES, February 3, 2026 -- HeartLung.AI , an AI-enabled company focused on early detection and prevention of heart disease, lung cancer, osteoporosis, emphysema and fatty liver disease using widely available CT scans, announced that its AutoChamber™ and AutoBMD™ AI services will be available through Precision Imaging Network, part of Mic

New Orleans, LA — HeartLung Corporation announced today that CommonSpirit Memorial Hospital-Breathe Easy Mobile Lung Screening , developed and led by HeartLung Scientific Advisor Dr. Robert Headrick, MD, MBA , is being featured this week at the Society of Thoracic Surgeons (STS) Annual Meeting in New Orleans. Breathe Easy was created to address a persistent challenge in lung cancer prevention: many high-risk individuals do not complete recommended screening due to real-wor